Selvita S.A.: Zlecenie na świadczenie usług badawczych przez spółkę zależną (2024-07-01)

Receipt of a significant purchase order by a company affiliated with Selvita S.A.

The Management Board of Selvita S.A., with its registered office in Krakow (“Issuer”, “Company”), with reference to current report No. 13/2023 dated September 25, 2023, hereby informs that on June 30, 2024, the company affiliated with the Issuer – company Selvita d.o.o., received three purchase orders for research services expanding the scope of existing cooperation under a framework of Master Service Agreement entered into on July 16, 2015, amended on July 18, 2022 (the "Orders") between the Company and one of the world's largest biopharmaceutical companies (the "Client").

The subject of the Orders, which will be executed from July 1, 2024 until July 31, 2025, are integrated ADME/DMPK (absorption, distribution, metabolism and excretion / drug metabolism and pharmacokinetics) support services, including physicochemical profiling services, analytical services and in-vivo PK (pharmacokinetics) studies for large and small molecules to support the Client's research programs. The Orders will be predominantly carried out at the laboratory in Zagreb.

The total value of the agreement amounts to EUR 2,965,000 (which equates to PLN 12,743,867 when converted at the average exchange rate of the National Bank of Poland on July 1, 2024, where 1 EUR = 4,2981 PLN). In 2024, services amounting to EUR 1,235,417 (which equates to PLN 5,309,946 when converted at the average exchange rate of the National Bank of Poland on July 1, 2024, where 1 EUR = 4,2981 PLN) will be provided.

The Orders received represent a continuation of the existing cooperation with the Client. The total value of services performed for the Client in the first six months of 2024 amounted to PLN 22,158,647.

Taking into account the value of the Orders, as well as the fact of continuation of significant cooperation between the Client and the Company, the Issuer's Management Board considers the Orders received to be important for the implementation of the Selvita Group's long-term plans to build a strong position as a leading provider of services in the area of support for drug discovery and development projects, as well as to increase cooperation with pharmaceutical companies.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions, or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Selvita S.A., its representatives, and employees decline all responsibility in this regard.